Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Medulloblastoma 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Neuroectodermal Tumors, Primitive 1Neuroectodermal Tumors 1Neoplasms 1Nasopharyngeal Carcinoma 1Brain Neoplasms 1

Interventions

Cisplatin 123Gemcitabine 70Radiotherapy, Intensity-Modulated 56toripalimab 39Capecitabine 36Fluorouracil 33Docetaxel 32Radiotherapy 24camrelizumab 23Drug Therapy 20nimotuzumab 18spartalizumab 13pembrolizumab 13nedaplatin 12apatinib 11Chemoradiotherapy 11tislelizumab 10sintilimab 10Nivolumab 10Magnetic Resonance Spectroscopy 10Induction Chemotherapy 10Immune Checkpoint Inhibitors 10Specimen Handling 9Cetuximab 9Carboplatin 9endostar protein 8Paclitaxel 8Bevacizumab 8anlotinib 7Radiation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Nasopharyngeal Carcinoma × Maintenance Chemotherapy × Clear all
NCT04319471 2020-03-24

Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

Fujian Cancer Hospital

Phase 2 Unknown
70 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡